TLSI Q4 2025: 60% Revenue Surge Supports Strategic Commercial Expansion
TriSalus Life Sciences achieved a robust 60% revenue increase in Q4 driven by expanding adoption of its TriNav infusion system and proprietary PEDD platform. The company is aggressively scaling its commercial footprint and clinical evidence generation, positioning for accelerated growth in 2026 despite near-term revenue cadence shifts. Capital raised enhances strategic execution across liver and emerging non-liver indications.
Summary
- Commercial Expansion Commitment: TriSalus is doubling its sales force to accelerate adoption and deepen market penetration.
- Clinical Validation Focus: Investments in foundational studies aim to reinforce PEDD's clinical and economic advantages.
- Strategic Product Portfolio Growth: New device launches broaden application scope beyond liver, targeting $2.8 billion addressable market.
Business Overview
TriSalus Life Sciences is an oncology-focused medical technology company specializing in pressure-enabled drug delivery (PEDD) technology integrated with its TriNav infusion systems. The company generates revenue primarily through sales of its FDA-cleared TriNav devices used in embolization procedures for solid tumors, with a focus on liver-directed therapies and expanding into non-liver indications such as thyroid and uterine artery embolization.
Performance Analysis
In the fourth quarter of 2025, TriSalus reported $13.2 million in revenue, marking a 60% year-over-year increase and a 14% sequential rise, driven predominantly by increased sales of the TriNav system in liver embolization applications. For the full year, revenue reached $45.2 million, up 53% from 2024, underscoring strong commercial momentum and effective execution of the company’s growth strategy. Gross margin improved to 86.7% in Q4, reflecting gains in manufacturing efficiency for new product launches, despite a slight year-over-year margin decline for the full year due to earlier scale-up inefficiencies.
Operating expenses reflected strategic shifts with R&D spending declining by $2.7 million year-over-year following the completion of nelitolimod clinical trials, while sales and marketing expenses increased by $2.9 million, primarily from performance-based compensation linked to higher sales volumes. General and administrative costs rose modestly, influenced by non-cash stock compensation and patent expense reclassification. The company narrowed its operating loss substantially, highlighting improved operating leverage amid expanding revenue. Adjusted EBITDA loss improved significantly to $0.9 million in Q4 from $5.7 million a year earlier, indicating progress toward profitability as investments ramp.
- Revenue Growth Driver: Liver-directed TriNav unit sales remain the core growth engine, with emerging applications poised to contribute meaningfully in the second half of 2026.
- Margin Dynamics: Manufacturing scale and product portfolio expansion are enhancing gross margins, though early-stage product launches exert temporary pressure.
- Expense Allocation Shift: Increased commercial investment aligns with strategic priorities to expand market coverage and physician engagement.
Overall, the financial results reflect a company transitioning from early-stage clinical development to commercial scale-up, leveraging its proprietary PEDD platform to capture a growing share of embolization markets.
Executive Commentary
"We are pleased to have exceeded our 2025 revenue guidance, reflecting strong commercial execution and sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver."
Mary Zella, President and CEO
"The increase in revenue and margin contribution highlights our strong operating leverage. We are investing to scale our commercial footprint, positioning us for meaningful growth and improved profitability exiting 2026."
David Patience, Chief Financial Officer
Strategic Positioning
1. Accelerated Commercial Expansion
TriSalus is aggressively expanding its sales force, effectively doubling its commercial footprint and adding a management layer to support scale. This expansion targets enhanced geographic coverage and deeper penetration in both established liver markets and emerging non-liver applications. The company employs a clinical specialist-representative pairing model to ensure strong physician support and product expertise, facilitating adoption across complex vascular anatomies.
2. Broadening Device Portfolio
The TriNav product suite has grown from two core products to seven differentiated offerings addressing diverse embolization challenges. The recent launch of TriNav XP, designed for larger embolic particles and improved trackability, has been met with positive clinical feedback. The upcoming TriNav Advance device aims to enable selective therapy delivery via standard microcatheters, expanding the addressable market and enhancing mapping and simulation procedures.
3. Clinical Evidence and Reimbursement Initiatives
TriSalus is investing in foundational clinical registries and studies, including the PROTECT registry for thyroid embolization and pilot studies for genicular artery embolization (GAE). The expansion of CMS reimbursement codes, particularly HCPCS C8004 for simulation procedures, effectively doubles the reimbursable use cases for TriNav, supporting broader adoption. The company plans multiple data releases in 2026 to underpin clinical and economic value propositions.
4. Nelitolimod Development and Partnership Focus
While clinical data updates for nelitolimod have been delayed to consolidate Phase 1 trial results, the company maintains commitment to this immunotherapeutic program through partnership discussions and investigator-initiated studies. Internal development spending has been reduced to preserve capital for near-term commercial priorities.
5. Capital Strength and Governance Enhancements
The $46 million gross proceeds raised in February 2026 provide substantial growth capital to fund commercial expansion, clinical initiatives, and product innovation. The appointment of healthcare investor Michael Stansky to the board adds seasoned oversight in capital markets and governance, supporting value creation as the company scales.
Key Considerations
TriSalus is at a critical inflection point, balancing near-term investments with long-term growth potential in a competitive interventional radiology market. The following points are central to evaluating the company’s trajectory:
- Commercial Scalability: The ability to effectively onboard and ramp a substantially larger sales organization will be pivotal to realizing revenue growth targets.
- Product Adoption Curve: Broadening the device portfolio enhances clinical flexibility, but physician education and procedural integration remain essential.
- Clinical Data Impact: Upcoming registry and trial results will influence physician confidence, payer reimbursement, and market penetration, particularly in non-liver indications.
- Capital Deployment Discipline: Efficient use of recent financing to accelerate growth without compromising financial stability is critical amid ongoing operating losses.
- Partnership Execution: Progress in nelitolimod collaborations could unlock additional value, but timing and outcomes remain uncertain.
Risks
TriSalus faces risks including potential delays or setbacks in clinical trial data releases, challenges in scaling commercial operations, and evolving reimbursement landscapes. The company’s ongoing operating losses and reliance on capital markets for funding heighten financial risk. Competitive pressures in embolization technologies and regulatory uncertainties could also impact growth.
Forward Outlook
For the first quarter of 2026, TriSalus expects revenue growth weighted toward the second half of the year due to commercial expansion onboarding and new product contributions. Full-year 2026 revenue guidance is reaffirmed at $60 million to $62 million. Management anticipates continued strong physician engagement and utilization of the PEDD platform, supported by upcoming product launches and clinical data releases. Visibility on adjusted EBITDA breakeven remains limited, with more clarity expected later in the year as investments mature.
Takeaways
TriSalus is transitioning from a clinical-stage company to a commercial growth enterprise, leveraging its proprietary PEDD technology to expand market share in liver embolization and diversify into new indications.
- Commercial Footprint Expansion: Doubling the sales force and adding management layers reflects a strategic commitment to scale and market penetration, critical to accelerating adoption across a $2.8 billion addressable embolization market.
- Product Portfolio Depth: The expanded TriNav suite addresses complex vascular anatomies, increasing procedural flexibility and supporting broader clinical use cases, which should drive higher utilization per account.
- Clinical and Reimbursement Momentum: Foundational registries and CMS code expansions underpin the platform’s value proposition, with data releases expected to catalyze uptake in non-liver indications during 2026.
Conclusion
TriSalus delivered a strong Q4 and full-year 2025 performance marked by robust revenue growth and margin improvement. The company’s strategic investments in commercial scale, clinical validation, and product innovation position it well for accelerated growth in 2026 and beyond, though execution risks and capital deployment discipline remain key factors for investors to monitor.
Industry Read-Through
TriSalus’ results highlight the growing importance of specialized drug delivery technologies in interventional oncology and radiology. The expansion of reimbursement codes and clinical evidence generation are critical enablers for technology adoption across embolization procedures. Other medtech companies targeting vascular and tumor therapies may find similar opportunities and challenges in balancing clinical innovation with commercial scale. The company’s approach to pairing clinical specialists with sales representatives could serve as a model for complex device adoption in physician-driven markets.